Social Media Ideas for Tris Pharma

Tris Pharma debuts Adneuris Therapeutics in new approach to pain management

Tris Pharma launched Adneuris Therapeutics on July 9 to advance a vision for pain medicine through the development and future commercialization of cebranopadol, its lead investigat...

<![CDATA[TrumpRx Expands to Offer Generic Medications]]>

<![CDATA[Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics]]>

Granules India gets First-To-File status for generic Lumryz tablets in US

This was Granules’ second Sole First-to-File ANDA, following its earlier approval for Amphetamine Extended-Release Tablets,

FDA approves Tryngolza to reduce acute pancreatitis risk

The FDA has approved olezarsen as the first and only therapy, alongside diet, to lower triglycerides and acute pancreatitis risk in patients with severe hypertriglyceridemia, accor...

<![CDATA[Parabilis Medicines Raises $670 Million in Initial Public Offering ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Sends Complete Response Letter for Cingulate's CTx-1301]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics]]>

Jazz Patent Suit Over Xyrem Survives Dismissal In NJ

A New Jersey federal judge has refused to let generic-drug company Tris Pharma Inc. escape a suit claiming its attempt to sell a competing version of Jazz Pharmaceuticals' narcolep...

<![CDATA[Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpha...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Datroway]]>

A migraine drugmaker heads to the public markets through reverse merger

Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing...

<![CDATA[Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion]]>

<![CDATA[FDA Sends CRL to Cingulate for CTx-1301]]>

CVS Caremark reaches settlement with FTC over insulin suit

Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost ver...

<![CDATA[Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs]]>

<![CDATA[Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex...

Alvotech (ALVO) Receives FDA Form 483 Following Routine Facility Inspection

<![CDATA[Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo]]>

Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain

Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts

TG Therapeutics rises on early-stage trial data for Briumvi injectable

<![CDATA[Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics]]>

<![CDATA[U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report ]]>